Tyrosine kinase inhibitors induce alternative spliced BCR-ABL
Adult
Aged
Alternative Splicing
Female
Fusion Proteins, bcr-abl
/ genetics
Gene Expression Regulation, Leukemic
/ drug effects
Genetic Loci
High-Throughput Nucleotide Sequencing
Humans
Introns
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ diagnosis
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ pharmacology
RNA Polymerase II
/ antagonists & inhibitors
Single-Cell Analysis
BCR-ABL
BCR-ABLIns35bp
MRD
alternative splicing
chronic myeloid leukemia
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
06
01
2020
revised:
16
03
2020
accepted:
22
03
2020
pubmed:
22
4
2020
medline:
11
8
2020
entrez:
22
4
2020
Statut:
ppublish
Résumé
To elucidate dynamic changes in native BCR-ABL and alternatively spliced tyrosine kinase inhibitor (TKI)-resistant but function-dead BCR-ABL
Identifiants
pubmed: 32314454
doi: 10.1111/cas.14424
pmc: PMC7385367
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
RNA Polymerase II
EC 2.7.7.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2361-2373Subventions
Organisme : Bristol-Myers Squibb
Organisme : Grant-in-Aid for Scientific Research
ID : 16H05340
Organisme : Grant in Aid for Scientific Research on Innovative Areas "Stem Cell Aging and Disease"
Organisme : Ministry of Education, Culture, Sports, Science and Technology of Japan
ID : 25115002
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
N Engl J Med. 2011 Oct 13;365(15):1384-95
pubmed: 21995386
Mol Cell Biol. 2004 Oct;24(20):8963-9
pubmed: 15456870
Cancer Cell. 2011 Oct 18;20(4):420-3
pubmed: 22014568
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
Blood. 2013 Aug 8;122(6):999-1006
pubmed: 23775717
Blood. 2007 Jan 1;109(1):58-60
pubmed: 16973963
Clin Cancer Res. 2011 Nov 1;17(21):6812-21
pubmed: 21903771
J Immunol. 2008 Jun 1;180(11):7358-67
pubmed: 18490735
Leuk Res. 2016 Oct;49:108-12
pubmed: 27658269
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332
Nucleic Acids Res. 2013 Feb 1;41(3):1591-603
pubmed: 23275552
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
N Engl J Med. 2011 Dec 29;365(26):2497-506
pubmed: 22150006
Mol Cell Biol. 2007 Jan;27(1):384-94
pubmed: 17043109
Blood. 2011 Nov 10;118(19):5250-4
pubmed: 21908430
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Cancer Sci. 2020 Jul;111(7):2361-2373
pubmed: 32314454
J Clin Oncol. 2014 Feb 10;32(5):424-30
pubmed: 24323036
Mol Cancer Ther. 2008 Dec;7(12):3834-41
pubmed: 19056677
J Mol Biol. 2016 Jun 19;428(12):2623-2635
pubmed: 27107644
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Blood. 2008 Dec 1;112(12):4437-44
pubmed: 18716134
Acta Haematol. 2009;121(1):27-31
pubmed: 19332983
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Nat Chem Biol. 2007 Sep;3(9):576-83
pubmed: 17643111
Leuk Res. 2014 Jan;38(1):76-83
pubmed: 24262285
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Nat Med. 1996 May;2(5):561-6
pubmed: 8616716
Nucleic Acids Res. 2009 May;37(9):e67
pubmed: 19339519
Blood. 2010 Nov 11;116(19):3758-65
pubmed: 20679528
J Mol Diagn. 2008 Mar;10(2):177-80
pubmed: 18276770
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
BMC Genomics. 2011 Oct 20;12:516
pubmed: 22011111
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17807-12
pubmed: 17098862
Cancer Sci. 2017 Nov;108(11):2204-2212
pubmed: 28801986
N Engl J Med. 2006 Jun 15;354(24):2531-41
pubmed: 16775234